"The U.S. Food and Drug Administration today approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A. Eloctate is the first Hemophilia A treatment designed to require less fre"...
RIXUBIS is contraindicated in patients who have:
- Known hypersensitivity to RIXUBIS or its excipients including hamster protein
- Disseminated Intravascular Coagulation (DIC) [see WARNINGS AND PRECAUTIONS]
- Signs of fibrinolysis [see WARNINGS AND PRECAUTIONS]
Last reviewed on RxList: 3/25/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Rixubis Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.